Generation and characterization of a cold-adapted attenuated live H3N2 subtype influenza virus vaccine candidate
- PMID: 20092795
Generation and characterization of a cold-adapted attenuated live H3N2 subtype influenza virus vaccine candidate
Abstract
Background: H3N2 subtype influenza A viruses have been identified in humans worldwide, raising concerns about their pandemic potential and prompting the development of candidate vaccines to protect humans against this subtype of influenza A virus. The aim of this study was to establish a system for rescuing of a cold-adapted high-yielding H3N2 subtype human influenza virus by reverse genetics.
Methods: In order to generate better and safer vaccine candidate viruses, a cold-adapted high yielding reassortant H3N2 influenza A virus was genetically constructed by reverse genetics and was designated as rgAA-H3N2. The rgAA-H3N2 virus contained HA and NA genes from an epidemic strain A/Wisconsin/67/2005 (H3N2) in a background of internal genes derived from the master donor viruses (MDV), cold-adapted (ca), temperature sensitive (ts), live attenuated influenza virus strain A/Ann Arbor/6/60 (MDV-A).
Results: In this presentation, the virus HA titer of rgAA-H3N2 in the allantoic fluid from infected embryonated eggs was as high as 1:1024. A fluorescent focus assay (FFU) was performed 24-36 hours post-infection using a specific antibody and bright staining was used for determining the virus titer. The allantoic fluid containing the recovered influenza virus was analyzed in a hemagglutination inhibition (HI) test and the specific inhibition was found.
Conclusion: The results mentioned above demonstrated that cold-adapted, attenuated reassortant H3N2 subtype influenza A virus was successfully generated, which laid a good foundation for the further related research.
Similar articles
-
Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.Vaccine. 2007 Oct 16;25(42):7379-84. doi: 10.1016/j.vaccine.2007.08.011. Epub 2007 Aug 24. Vaccine. 2007. PMID: 17870216
-
Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus.Vaccine. 2006 Mar 10;24(11):1966-74. doi: 10.1016/j.vaccine.2005.10.051. Epub 2005 Nov 8. Vaccine. 2006. PMID: 16343703
-
Genetic engineering of live attenuated influenza viruses.Methods Mol Biol. 2012;865:163-74. doi: 10.1007/978-1-61779-621-0_10. Methods Mol Biol. 2012. PMID: 22528159
-
[Live cold-adapted influenza vaccine: state-of-the-art].Vopr Virusol. 2011 Jan-Feb;56(1):4-17. Vopr Virusol. 2011. PMID: 21427948 Review. Russian.
-
The development of live attenuated cold-adapted influenza virus vaccine for humans.Rev Med Virol. 1999 Oct-Dec;9(4):237-44. doi: 10.1002/(sici)1099-1654(199910/12)9:4<237::aid-rmv252>3.0.co;2-g. Rev Med Virol. 1999. PMID: 10578119 Review.
Cited by
-
Rapid strategy for screening by pyrosequencing of influenza virus reassortants--candidates for live attenuated vaccines.PLoS One. 2014 Mar 19;9(3):e92580. doi: 10.1371/journal.pone.0092580. eCollection 2014. PLoS One. 2014. PMID: 24647786 Free PMC article.
-
Application of real time RT-PCR for the genetic homogeneity and stability tests of the seed candidates for live attenuated influenza vaccine production.J Virol Methods. 2014 Jan;195:18-25. doi: 10.1016/j.jviromet.2013.09.003. Epub 2013 Sep 18. J Virol Methods. 2014. PMID: 24056261 Free PMC article.
-
The new temperature-sensitive mutation PA-F35S for developing recombinant avian live attenuated H5N1 influenza vaccine.Virol J. 2012 May 23;9:97. doi: 10.1186/1743-422X-9-97. Virol J. 2012. PMID: 22621130 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical